Among patients with blood eosinophil counts greater than or equal to 150 cells/µL, the reduction in the annual rate of moderate to severe COPD exacerbations was found to be nominally significant. The ...
GlaxoSmithKline’s (GSK) Nucala (mepolizumab) has been approved by the MHRA to treat adults with uncontrolled chronic ...
The approval is based on two placebo-controlled phase 3 studies, which showed mepolizumab significantly reduced the annualised rate of moderate/severe exacerbations and time to first moderate/severe ...
Many people with COPD can control their symptoms by using inhaled medicines each day. But inhaled medicines may not offer enough relief for people who also have high levels of a type of white blood ...
GSK has high hopes for Nucala thanks to its less frequent dosing – once a month, versus every other week for Dupixent – and the broader label. The company has estimated that among people with COPD who ...
We currently know that COPD, and specifically emphysema, is not just a lung disease found alongside lung cancer; it increases ...
AJMC®: What recent developments in the therapeutic landscape of chronic obstructive pulmonary disease (COPD) do you think have the greatest potential to shift how treatment is managed? Dr Martinez: ...
While COPD (chronic obstructive pulmonary disease) symptoms may start out as mild to moderate — with episodes of difficulty breathing that come and go — over time, COPD tends to get worse, and many ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback